secondary liver cancer Cancer
patient’s response
cancer cells
patient’s tumour
metastatic liver cancer
prediction of drug response
secondary cancers
lack of response
treatment cycle
patient’s therapy cycle
primary tumour
choice of treatment
efficient drug treatments
D micro-tumour
drugs
wide range of treatment options
clear guidelines
patient’s survival time
trial
error
D advanced test
inefficient therapies
individualised drug testing platform
line treatments
guideline therapies
SpheroPredict project
particular types of primary cancers
leading causes of death
urgent need
EU healthcare system
spheroid
order
proven efficacy
model
international institutions
low toxicity
financial perspectives
economic burden
quality of life
chemoresistance
productivity loss
deathliest diseases
high risk of metastasizing
era of personalised medicine
tumours
end
patients
approach
chemotherapy
SpheroTec
locations
deaths
year
Europe
success
commercialisation
century
feasibility
innovative solution
body
Phase